Showing results (261-270 of 419) with videos related to
Sort By:
Pageof 42
Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.Cancer|December 10, 2015
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Kai Wang, Depinder Khaira, et al.Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyVivek Subbiah, Irene Braña, Alessandra Longhi, et al.Leukemia & Lymphoma|November 10, 2017
Myeloid/lymphoid neoplasms with FGFR1 rearrangementPaolo Strati, Guilin Tang, Dzifa Y Duose, et al.Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.Pageof 42